Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials - Wikidata - awgldk - TriplyDB

Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials

Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials

http://www.wikidata.org/entity/Q28304657

about

Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis.Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials.Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination.A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease Renin inhibitors and cardiovascular and renal protection: an endless quest?Renin inhibition in the treatment of diabetic kidney disease.Renin Inhibition with Aliskiren: A Decade of Clinical Experience.

P2860

Q34247173-719CC50E-3E71-4A67-962F-5F11D1CCD735 Q34478776-991C6A2F-82BA-477C-9CCE-A37B4B2B009F Q35408572-F5ACF4A5-DB36-441F-A799-DE6EC72E0565 Q36975796-049DC4C3-ECF1-472B-B050-70ED01E6425D Q37322017-2B2210AB-E9F0-4EA3-A99A-BCCB31DE8FB0 Q37990796-91C6FE9A-DCEC-4BC6-858B-7B787A70EED7 Q38075571-050DCD47-D85B-4F6A-B8EE-24408129D870 Q38672900-9DFB92C2-C4B1-493E-8E93-D51940E0C00C

P2860

Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials

http://www.wikidata.org/entity/Q28304657

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@ast

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@en

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@nl

type

label

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@ast

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@en

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@nl

prefLabel

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@ast

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@en

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@nl

P1433

Q28304657-71A15E18-780F-4BAE-BF7E-D100AAEBB5CA

P1476

Q28304657-2F230CF6-4358-41AD-ABA0-A1974E9F40C6

P2093

Q28304657-00BC7827-0188-4728-85A6-E32BF370FBB1

Q28304657-3B297C48-43A3-4175-902A-0B82C0D0B13A

Q28304657-61533AF3-FA9D-4DED-8C35-9B64A842570A

Q28304657-923F4531-396E-4921-8EF2-013C1D840DB9

Q28304657-A8B7A0BD-E542-478F-9ECB-7ECB754DC5DD

Q28304657-FF0672BA-3284-48B7-9DD3-037AC86211DE

P2860

Q28304657-0E3A4769-84D8-4E37-9363-AD58FD925E4E

Q28304657-1BA875BE-773C-42E8-A543-D454A304A5FB

Q28304657-24FB3DBE-C462-409C-8704-E35BFF0AEA4C

Q28304657-25138E30-677F-4514-86FD-4E532B2D0E6C

Q28304657-2D946E8A-C102-49E7-9878-3EE8970C6F46

Q28304657-37376491-C82F-48B4-9C89-DF422913F13F

Q28304657-7989B885-8647-4BEC-A9CD-4C6B56B4CEBA

Q28304657-79F5CA66-E15B-4FA8-931C-1EB7EBB5DA68

Q28304657-7A05BD61-6894-412D-A879-3B23475D1652

Q28304657-8267E43C-016A-415C-9AFA-BEB1056A9574

P304

Q28304657-6BEA8E80-38BC-48F3-AB09-710DC9279E5A

P31

Q28304657-BE6E788E-1BB6-4299-A53C-B94C6C2B4BC6

Q28304657-E6051958-45D8-4210-A371-4FC420F25E7E

P356

Q28304657-0E1076C3-24D3-41B4-AAE2-A3E3FF302AC0

P407

Q28304657-481A5924-3796-41BC-A055-7AD33B12C006

P433

Q28304657-68A58633-5032-4CB1-AB0E-358B73D01E3A

P478

Q28304657-A245CFC5-B631-469C-AB86-00D83DF3DE45

P577

Q28304657-4C9C57F7-5A44-4A89-B5F8-C1A32B7AEB89

P698

Q28304657-5B5A9882-5EF4-4424-8CB9-2CB5696EF5E2

P921

Q28304657-ED6CFF2C-3044-4523-820F-51580D88C5E2

P356

P1433

American Journal of Hypertension

P1476

Aliskiren vs. angiotensin rece ...... f randomized controlled trials

@en

P2093

Dengfeng Gao

http://www.w3.org/2001/XMLSchema#string

Guanghua Hao

http://www.w3.org/2001/XMLSchema#string

Jin Wei

http://www.w3.org/2001/XMLSchema#string

Ning Ning

http://www.w3.org/2001/XMLSchema#string

Ping Sun

http://www.w3.org/2001/XMLSchema#string

Xiaolin Niu

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

Renin inhibition: what are the therapeutic opportunities?

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome.

Cardiovascular morbidity and mortality in high-risk populations: epidemiology and opportunities for risk reduction.

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.

Protective effects of renin-angiotensin blockade beyond blood pressure control.

Progression of cardiovascular damage: the role of renin-angiotensin system blockade.

P304

613-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJH.2011.3

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21293386

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension